A SAFETY AND EFFICACY TRIAL EVALUATING THE USE OF APIXABAN FOR THE EXTENDED TREATMENT OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM (Apixaban after the initial Management of PuLmonary embolIsm and deep vein thrombosis with First-line therapY- EXTended treatment. The AMPLIFY-EXT study) [Extension of 700032384].

Trial Profile

A SAFETY AND EFFICACY TRIAL EVALUATING THE USE OF APIXABAN FOR THE EXTENDED TREATMENT OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM (Apixaban after the initial Management of PuLmonary embolIsm and deep vein thrombosis with First-line therapY- EXTended treatment. The AMPLIFY-EXT study) [Extension of 700032384].

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Sep 2016

At a glance

  • Drugs Apixaban (Primary)
  • Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
  • Focus Adverse reactions; Biomarker; Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms AMPLIFY-EXT
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 12 Sep 2016 Results of this and two other trials (AMPLFY and AMPLIFY J) published in the Drugs (2016).
    • 08 Oct 2015 Results published in the Thrombosis and Haemostasis
    • 29 Jul 2014 According to a Bristol-Myers Squibb media release, apixaban has been approved by the European Commission for the treatment of deep vein thrombosis and pulmonary embolism on the basis of this and the AMPLIFY trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top